Treatment - Page 2 of 378 Posts on Medivizor
Navigation Menu

Treatment Posts on Medivizor

Can high-risk prostate cancer be treated with high-dose-rate brachytherapy, external beam radiotherapy plus long-term androgen deprivation therapy?

Can high-risk prostate cancer be treated with high-dose-rate brachytherapy, external beam radiotherapy plus long-term androgen deprivation therapy?

Posted by on Aug 9, 2020 in Prostate cancer | 0 comments

In a nutshell This study looked at whether the use of high-dose (HD) brachytherapy (BT) and hypofractionated external beam radiotherapy (EBRT) plus androgen-deprivation therapy (ADT) as a means of treatment for very high-risk prostate cancer (PCa). The study found that this treatment had significant benefits for patients with high-risk...

Read More

Combining daratumumab with carfilzomib and dexamethasone to treat patients with relapsed or refractory multiple myeloma

Combining daratumumab with carfilzomib and dexamethasone to treat patients with relapsed or refractory multiple myeloma

Posted by on Jul 31, 2020 in Multiple Myeloma | 0 comments

In a nutshell The study evaluated outcomes of the combination of carfilzomib (Kyprolis; K), dexamethasone (Decadron; d), and daratumumab (Darzalex; D) in patients with relapsed or refractory (r/r) multiple myeloma (MM). The authors found that KdD was safe and effective to improve progression-free survival (PFS) in such patients compared to...

Read More

Backward walking training improves walking and balance in stroke survivors

Backward walking training improves walking and balance in stroke survivors

Posted by on Jul 31, 2020 in Stroke | 0 comments

In a nutshell This study investigated the effectiveness of backward walking (BW) training in the treatment of patients with stroke. Researchers suggested that BW improves walking, including speed and balance in stroke survivors. Some background Stroke is a major health problem in the US with more than 795,000 new cases every year. It happens when the...

Read More

Is there an association between statin use and the risk of prostate cancer mortality?

Is there an association between statin use and the risk of prostate cancer mortality?

Posted by on Jul 31, 2020 in Prostate cancer | 0 comments

In a nutshell This study evaluated whether there was an association between statin (a type of cholesterol-lowering medication) use and prostate cancer (PCa) mortality. This study found that stain use resulted in lower rates of PCa-specific mortality, in particular with the use of hydrophilic statins. Some background PCa is one of the most common...

Read More

Axicabtagene ciloleucel for aggressive B-cell lymphoma outside clinical trials

Axicabtagene ciloleucel for aggressive B-cell lymphoma outside clinical trials

Posted by on Jul 28, 2020 in Non-Hodgkin lymphoma | 0 comments

In a nutshell This study looked at axicabtagene ciloleucel (Yescarta) to treat B-cell non-Hodgkin lymphoma which has returned after previous treatment outside of clinical trials. It found that most patients responded to this immune therapy and that some patients had a complete response. Some background B-cell non-Hodgkin lymphomas (NHL) are a group of...

Read More

Comparing the effectiveness of apalutamide, darolutamide and enzalutamide in treating nonmetastatic castration-resistant prostate cancer

Comparing the effectiveness of apalutamide, darolutamide and enzalutamide in treating nonmetastatic castration-resistant prostate cancer

Posted by on Jul 26, 2020 in Prostate cancer | 0 comments

In a nutshell The study compared outcomes of apalutamide (A; Erleada), darolutamide (D; Nubeqa), and enzalutamide (E; Xtandi) in treating nonmetastatic castration-resistant prostate cancer (nmCRPC). The authors found that A and E had better metastasis-free survival (MFS) compared to D. Some background Men with CRPC fail to respond to...

Read More

Long term outcomes for children with acute lymphoblastic leukemia treated with the SCMC-ALL-2009 protocol

Long term outcomes for children with acute lymphoblastic leukemia treated with the SCMC-ALL-2009 protocol

Posted by on Jul 26, 2020 in Leukemia | 0 comments

In a nutshell This study aimed to investigate the long-term treatment outcomes and prognostic factors of acute lymphoblastic leukemia (ALL) in pediatric patients who took part in the SCMC-ALL-2009 trials.   This study concluded that the long-term outcomes were favorable for these patients and better for low-risk patients...

Read More

Panitumumab and capecitabine improves the outcomes of older patients with advanced colorectal cancer

Panitumumab and capecitabine improves the outcomes of older patients with advanced colorectal cancer

Posted by on Jul 26, 2020 in Colorectal cancer | 0 comments

In a nutshell This study investigated the effectiveness of panitumumab (Vectibix) and capecitabine (Xeloda) combination to treat older patients with advanced colorectal cancer (CRC). Researchers suggested that this combination is a good and safe treatment for older patients with CRC. Some background CRC is a common cancer worldwide. CRC patients are...

Read More

What are the long-term effects of prostatic artery embolization on benign prostatic hyperplasia?

What are the long-term effects of prostatic artery embolization on benign prostatic hyperplasia?

Posted by on Jul 26, 2020 in Benign prostatic hyperplasia | 0 comments

In a nutshell This study aimed to investigate the long-term effects of prostatic artery embolization (PAE) in benign prostatic hyperplasia. The main finding was that PAE was a safe and effective long-term treatment. Some background Benign prostatic hyperplasia (BPH) is a non-cancerous condition in which the prostate gland is larger than usual....

Read More